HLS Therapeutics Inc.
HLS
Kedudukan dalam Saham
#22029
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Harga Saham
$2.98
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$92.18M
Perubahan (1 hari)
-1.93%
Perubahan (1 tahun)
-25.88%
Negara
CA
Perdagangan HLS Therapeutics Inc. (HLS)
Kategori
Healthcare
Modal pasaran bagi HLS Therapeutics Inc.(HLS)
Modal Pasaran: $92.18M
Sehingga October 2026, HLS Therapeutics Inc. mempunyai modal pasaran sebanyak $92.18M. Ini menjadikan HLS Therapeutics Inc. syarikat ke-22029th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran HLS Therapeutics Inc. dari 2010 hingga 2026
HLS berbanding dengan 5 teratas yang paling popular stocks
